Spyre Therapeutics, Inc. (SYRE) Financials

SYRE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 764.0 million 93.1 million
Dec. 31, 2025 777.8 million 62.5 million
Sept. 30, 2025 504.6 million 49.5 million
June 30, 2025 538.8 million 83.1 million

SYRE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -57.5 million 12.8 million
Dec. 31, 2025 -44.6 million 9.8 million
Sept. 30, 2025 -37.1 million 9.6 million
June 30, 2025 -46.6 million 9.4 million

SYRE Net Income

No data available :(

SYRE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 741.5 million - -
Dec. 31, 2025 756.5 million - -
Sept. 30, 2025 486.2 million - -
June 30, 2025 526.6 million - -

SYRE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 346.0 million
Dec. 31, 2025 346.0 million
Sept. 30, 2025 60.4 million
June 30, 2025 60.7 million

SYRE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 60.4 million 15.2 million -
Dec. 31, 2025 - 44.6 million 12.5 million -
Sept. 30, 2025 - 45.2 million 11.6 million -
June 30, 2025 - 40.1 million 11.8 million -

SYRE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 90.5 million 45.2 million
Sept. 30, 2025 - 45.2 million
June 30, 2025 - -

SYRE

Price: $83.58

52 week price:
13.93
83.58

Earnings Per Share: -2.12 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 4.7 billion

Links: